Sign In
Buy ARMP
$4.54
-0.240 (-5.02%)
At Close: Jul 31, 2026
Armata Pharmaceuticals (ARMP) Stock Jumps 12.2%: Will It Continue to Soar?
08:06am, Tuesday, 21'st Jul 2026
Armata Pharmaceuticals (ARMP) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
FDA submissions address all feedback on clinical, CMC, and regulatory topics from the End-of-Phase 2 meeting Four AP-SA02 engineering runs completed; clinical trial material production is the next pla
Fulfills important regulatory milestone for AP-SA02 on the path toward a future BLA and supports expansion into pediatric patients LOS ANGELES, July 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, In
Supports Phase 3 readiness of AP-SA02 Non-dilutive DoD funding totals $28.7M to date LOS ANGELES, June 23, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Co
Armata Pharmaceuticals Announces First Quarter 2026 Results and Provides Corporate Update
04:30pm, Wednesday, 13'th May 2026
Entered into secured credit agreement with Innoviva for $25 million maturing in 2029 LOS ANGELES, May 13, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Comp
Armata Pharmaceuticals Secures FDA Fast Track Designation for AP-SA02
07:00am, Thursday, 07'th May 2026
Enables more frequent FDA engagement, rolling Biologic License Application review, and the potential for Accelerated Approval and Priority Review upon successful clinical development Advances AP-SA02
Armata Pharmaceuticals Announces Structural Biology Publication in "Communications Biology"
07:00am, Monday, 04'th May 2026
Describes structure of phage P7-1, included in Armata's Pseudomonas aeruginosa phage cocktail, AP-PA02 LOS ANGELES, May 4, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Arm
Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D.
07:00am, Monday, 27'th Apr 2026
LOS ANGELES, April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi
Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2025 Financial Results
04:05pm, Wednesday, 25'th Mar 2026
LOS ANGELES, March 25, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi
Armata Pharmaceuticals Delays Announcement of Fourth Quarter and Full-Year 2025 Results and Provides Corporate Update
07:00am, Thursday, 19'th Mar 2026
LOS ANGELES, March 19, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of hi
Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) Designation for AP-SA02
07:00am, Monday, 23'rd Feb 2026
Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity and the potential for fast t
FDA agreed that data from the Phase 2a diSArm study support advancement of AP-SA02 to a Phase 3study First bacteriophage company to advance a clinical candidate to Phase 3 LOS ANGELES, Jan. 13, 2026 /
Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Shares Up 12.8% – Still a Buy?
01:50am, Thursday, 04'th Dec 2025
Armata Pharmaceuticals, Inc. (NYSEAMERICAN:ARMP - Get Free Report) was up 12.8% during trading on Wednesday. The stock traded as high as $5.99 and last traded at $5.99. Approximately 75,815 shares tra
LOS ANGELES , Nov. 18, 2025 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a clinical-stage biotechnology company focused on the development of high-pu
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
06:26pm, Wednesday, 12'th Nov 2025
Armata Pharmaceuticals, Inc. (ARMP) came out with a quarterly loss of $0.42 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.15 per share a year ago.
